Physician profile
Matthew Baer
NPI 1861978082
$15,487.10
in general payments reported to CMS, 2019-2025
51 companies · $6,996 in 2025
The $6,996 reported for 2025 was more than what 76% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.93 · 2022: $137 · 2023: $2,873 · 2024: $5,384 · 2025: $6,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,050 · Honoraria: $1,000 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,913.25 |
| Consulting Fee | $1,050.00 |
| Honoraria | $1,000.00 |
| Education | $290.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,750.43 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $2,168.38 | 2023-2025 | Zilbrysq, Rystiggo, Briviact |
| Pfizer INC. | $1,064.90 | 2023-2025 | |
| Natus Medical Incorporated | $1,000.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $910.66 | 2023-2025 | |
| Lundbeck LLC | $813.63 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $767.85 | 2023-2025 | Vumerity, Tysabri, Tecfidera |
| Lilly USA, LLC | $554.53 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $381.27 | 2023-2025 | Hyqvia |
| Argenx US, INC. | $368.75 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $341.27 | 2023-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $341.18 | 2023-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $340.44 | 2024-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $338.37 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $337.47 | 2023-2025 | Acthar |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $320.30 | 2023-2024 | |
| Genentech USA, INC. | $251.29 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Axsome Therapeutics, INC. | $182.84 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $176.41 | 2021-2025 | Ultomiris |
| Sk Life Science, INC. | $162.45 | 2023-2025 | |
| Amgen INC. | $151.94 | 2025 | Uplizna |
| Mdd US Operations, LLC | $150.47 | 2023-2025 | Gocovri, Gocovri |
| Catalyst Pharmaceuticals, INC. | $149.24 | 2023-2025 | Fycompa, Firdapse |
| Janssen Biotech, INC. | $148.96 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.83 | 2025 | Zeposia |
| Boston Scientific Corporation | $111.16 | 2024-2025 | General - Therapies, Ams 700 |
| Tg Therapeutics, INC. | $90.34 | 2025 | |
| Sumitomo Pharma America, INC. | $80.19 | 2023-2024 | Aptiom |
| Harmony Biosciences LLC | $69.04 | 2023 | Wakix |
| Azurity Pharmaceuticals, INC. | $68.03 | 2023-2025 | Horizant, Horizant |
| Acadia Pharmaceuticals INC | $67.55 | 2023-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $62.87 | 2025 | Wainua |
| Merz Pharmaceuticals, LLC | $58.25 | 2025 | Xeomin |
| Hospira, INC. | $55.65 | 2025 | |
| Csl Behring | $53.63 | 2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $48.80 | 2023-2024 | Rexulti |
| Microtransponder, INC. | $40.60 | 2025 | |
| Acorda Therapeutics, INC | $40.36 | 2023-2024 | Ampyra, Inbrija |
| Corium, LLC | $37.19 | 2023 | Adlarity |
| Octapharma USA, INC. | $36.52 | 2025 | Panzyga |
| Ipsen Biopharmaceuticals, INC | $35.97 | 2024-2025 | Dysport |
| Supernus Pharmaceuticals, INC. | $35.02 | 2025 | Qelbree |
| Ge Healthcare | $31.86 | 2025 | |
| Amneal Pharmaceuticals LLC | $28.95 | 2025 | Crexont |
| Genzyme Corporation | $25.87 | 2025 | |
| Tonix Medicines, INC. | $22.83 | 2025 | Zembrace Symtouch |
| Cala Health, INC. | $20.48 | 2025 | Cala Kiq |
| Medtronic, INC. | $18.62 | 2025 | Inceptiv |
| Averitas Pharma INC. | $18.21 | 2024 | Qutenza |
| Tanabe Pharma America, INC. | $17.83 | 2025 | Radicava |
| Xeris Pharmaceuticals, INC. | $16.42 | 2023 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Baer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.